10-K: WEED, Inc. 2025 Annual Report: Focus on Research and Asset Preservation

WEED, Inc. filed its 2025 10-K, detailing a year focused on asset preservation, strategic technology exploration, and continued development of its cannabis genomic study, while facing significant going concern risks.

Summary

• WEED, Inc. reported a net loss of $1,372,206 for the fiscal year ended December 31, 2025, an increase from the $510,716 net loss in 2024.
• The company's operating expenses rose significantly to $1,327,679 in 2025 from $529,992 in 2024, primarily due to increased general and administrative expenses.
• Revenue remained at $0 for both 2025 and 2024, as the company has not yet commercialized its research or entered its planned business segments.
• Cash on hand decreased to $33,130 at the end of 2025 from $159,355 at the end of 2024, with a monthly cash burn rate of approximately $10,500.
• The company continues to focus on its cannabis genomic study and integrating assets from the Hempirical Genetics acquisition, including a seedbank of over 250 strains.
• Strategic initiatives include exploring a digital asset ecosystem with Remergify, Inc., potentially launching WEEDCoin and BUDZCoin.
• The company holds significant real estate assets, notably the "Four Winds of Lake Erie" property in Portland, New York.
• Substantial doubt exists regarding the company's ability to continue as a going concern due to recurring losses and minimal cash.

Sentiment

Score: 2

Explanation: StockSavvy.ai views this filing as highly negative due to the significant increase in net loss, lack of revenue, dwindling cash reserves, and the explicit statement of substantial doubt regarding the company's ability to continue as a going concern.

Positives

• Maintained a proprietary seedbank of over 250 cannabis and hemp strains, including rare Landrace varieties.
• Continued development and cataloging of genetic assets to support future pharmaceutical research and consumer product strategies.
• Entered a strategic partnership to evaluate a digital asset ecosystem, potentially addressing banking and supply chain challenges.
• Maintained high-value real estate assets, such as the 44-acre "Four Winds of Lake Erie" property, providing a tangible asset base.
• Maintained industrial hemp licenses in Arizona, including cultivation, nursery, and processing permits.
• Successfully de-registered non-essential international subsidiaries to reduce overhead and simplify corporate governance.
• Continued engagement with Professor Elka Touitou for potential future collaboration on patent acquisition and clinical trials.

Negatives

• Reported a net loss of $1,372,206 for the year ended December 31, 2025, an increase from $510,716 in 2024.
• Operating expenses increased by $797,687 to $1,327,679 in 2025, primarily due to higher general and administrative expenses.
• Revenue remained at $0 for both 2025 and 2024.
• Cash on hand significantly decreased to $33,130 as of December 31, 2025, from $159,355 as of December 31, 2024.
• Total liabilities increased by $288,895 to $1,248,267 as of December 31, 2025, primarily due to increases in notes payable to related parties.
• The company has identified four material weaknesses in its internal controls over financial reporting.
• Substantial doubt exists regarding the company's ability to continue as a going concern.

Risks

• Substantial doubt about the company's ability to continue as a going concern due to recurring losses and minimal cash.
• Dependence on securing additional debt or equity financing to fund operations and research initiatives.
• The success of the cannabis genomic study and future product development is dependent on securing sufficient financing.
• The digital asset ecosystem initiative (WEEDCoin, BUDZCoin) is subject to capital availability and a complex, evolving regulatory framework.
• Potential for federal enforcement of cannabis laws, despite state-level legalization, could cause significant financial damage.
• The pharmaceutical industry may pose opposition or threats to the cannabis industry's development.
• Inability to adequately protect proprietary rights, including potential challenges to patent applications or the effectiveness of intellectual property protection.
• The company's common stock is thinly traded and subject to penny stock rules, potentially reducing trading activity and liquidity.

Future Outlook

The company's future outlook is heavily dependent on its ability to secure substantial additional funding to continue its cannabis genomic study, develop new products, and potentially enter the hemp and infused beverage market. Strategic initiatives include exploring digital assets, but these are in early development and subject to capital availability and regulatory frameworks. The company anticipates continued negative cash flows for the foreseeable future.

Management Comments

• Management believes its significant real estate holdings and proprietary seedbank provide a foundational asset base, though these assets are not currently liquid.
• The company's future is dependent on its ability to secure additional debt or equity financing.
• Management believes its unique gene-based breeding program will improve cultivars and introduce integrity, stability, and quality to the market.
• Management believes its genetic assets represent significant long-term strategic value as the federal regulatory environment for cannabis evolves.
• Management believes the "Four Winds of Lake Erie" property represents a key 'hard asset' that distinguishes the Company from peers in the microcap sector.

Industry Context

StockSavvy.ai notes that WEED, Inc.'s focus on cannabis genomics and bio-pharmaceutical development aligns with emerging trends in the cannabis industry, particularly the shift towards research-driven product development and the potential for medical applications. However, the company operates in a highly regulated and evolving market, facing significant challenges related to federal legality in the U.S. and the need for substantial capital investment.

Comparison to Industry Standards

• Competitors in the cannabis research market segment are evaluated based on research team experience, facilities, instrumentation, internal protocols, and scientific community relationships. WEED, Inc. claims to have experienced personnel, dedicated research space, advanced sequencing instrumentation, custom bioinformatics, and strong industry relationships.
• Companies like Canopy Growth Corporation, Aurora Cannabis, Cronos Group, Trulieve Cannabis Corp., TerrAscend Corporation, and Tilray Brands are mentioned as competitors in the broader cannabis industry, though WEED, Inc. currently focuses on the research segment.
• Other research entities like Colorado State Universities and Anandia Labs are noted for their work in cannabis genomics, with WEED, Inc. differentiating itself through proprietary bioinformatics and a unique two-sequencing approach.
• Phylos Biosciences is mentioned for DNA-based genetic fingerprinting to assist breeding programs, while New West Genetics focuses on industrial hemp development using modern sequencing technology.

Corporate Governance

Legal Proceedings

• In the ordinary course of business, the company is from time to time involved in various pending or threatened legal actions. Management believes these are not expected to have a material adverse effect on financial position or results of operations.

Related Party Transactions

• Lease of executive offices from Glenn E. Martin on a month-to-month basis ($1,200/month).
• Notes payable to related parties (Glenn Martin, Nicole Breen, Jeffrey Miller, Robert Leitzman, Sandra Orman) totaling $502,985 as of December 31, 2025.
• Accrued officer compensation owed to Glenn E. Martin ($273,000) and Nicole M. Breen ($96,750) as of December 31, 2025.
• Share issuances for services rendered to related parties or entities controlled by them, including Glenn E. Martin and Nicole M. Breen, on various dates.
• The company has no formal process related to the identification and approval of related party transactions, which is identified as a material weakness in internal controls.

Stakeholder Impact

• Shareholders face significant dilution risk from potential future equity financings and the ongoing lack of revenue and profitability.
• Employees (currently two full-time) and consultants are subject to the company's financial instability and the risks associated with its early-stage development.
• Creditors and lenders (including related parties) face increased risk due to the company's negative cash flow and substantial doubt about its going concern status.

Next Steps

• Continue cataloging genetic assets from Hempirical Genetics, LLC acquisition to support future research and product strategies.
• Evaluate the development of a digital asset ecosystem with Remergify, Inc., potentially launching WEEDCoin and BUDZCoin.
• Pursue funding to continue the Cannabis Genomic Study and enter the hemp and infused beverage market.
• Seek additional debt or equity financing to fund operations and research.
• Potentially pursue patent protection for new cannabis strains if successful in identifying promising candidates.

Key Dates

Recommendation

The company exhibits severe financial distress, with increasing losses, zero revenue, dwindling cash, and substantial doubt about its ability to continue as a going concern. While it possesses intellectual property and real estate assets, the path to profitability is highly uncertain and dependent on significant future capital raises, which carry substantial dilution risk. The identified material weaknesses in internal controls further add to the risk profile.

Keywords

WEED Inc., 10-K, Annual Report, Cannabis Genomics, Biopharmaceutical, Real Estate, Digital Assets, Going Concern